Microbiome Diversity
HaemaLogiX doses KMCAR T‑cell in KOALA trial
Discover the KMCAR T-cell dose in the KOALA Phase I trial, a promising CAR‑T option for relapsed or refractory kappa‑restricted multiple myeloma patients.
By Samoyed · Aug 30, 2026
Discover the KMCAR T-cell dose in the KOALA Phase I trial, a promising CAR‑T option for relapsed or refractory kappa‑restricted multiple myeloma patients.
Amgen's new drug shows promise in treating inflammatory diseases, potentially securing a new label addition for severe conditions like asthma and eosinophilic o
© 2026 Vimeo Health. All rights reserved.
Theme by Auto UI Theme Builder.